PATENT CLAIM ANALYSIS

Application Number: 16144365
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-04
Patent Classification: ["544", "350000"]

Abstract:
The present invention is directed to [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-a]pyrazine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.

Claim (Index 79):
The method of  claim 46 , wherein said disease is myelofibrosis.

Metadata:
- Claim Count in Document: 125.0
- Percentile: 97.0
- Lexical Diversity: 1.31034
- Patent Class: 544.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14795499', '15613379', '16130801', '14795466', '15613361']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8430893082864233
- 35 USC 102 Novelty (BERT): 0.6138847024815812
- Combined Prediction Score: 0.820168847705939
- Mean Citation Score: 628.13392
- Max Citation Score: 636.3204
- Similarity Product: 475.3829829106807

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test